HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology12 papers

Drug-induced interstitial lung disorder

Last edited: 4/15/2026

Overview

Drug-induced interstitial lung disorders encompass a range of pulmonary adverse reactions caused by medications, often manifesting as interstitial pneumonitis or other patterns of lung injury 1.

Diagnosis

  • Clinical Presentation: Symptoms include dyspnea, cough, and hypoxemia 1.
  • Diagnostic Tests: High-resolution computed tomography (HRCT) of the chest is crucial for identifying characteristic patterns of interstitial lung disease 1.
  • Pulmonary Function Tests (PFTs): Useful for assessing restrictive or obstructive patterns 1.
  • Bronchoalveolar Lavage (BAL): May help rule out infectious causes 1.
  • Drug History: Detailed history to identify potential offending agents 1.
  • Incidence Monitoring: Reports to adverse drug reaction advisory committees can provide insights into common culprits 1.

    • Management

  • Discontinuation of Offending Agent: Immediate cessation of the suspected drug 1.
  • Supportive Care: Oxygen therapy, mechanical ventilation if necessary 1.
  • Corticosteroids: First-line treatment for severe cases, dose typically titrated based on response 1.
  • Immunosuppressants: Considered in refractory cases, e.g., cyclophosphamide or mycophenolate mofetil 1.
  • Monitoring: Regular follow-up with PFTs and imaging to assess recovery 1.
  • Preventive Measures: Avoidance of known triggers in susceptible individuals 1.

    • Special Populations

  • Pregnancy: Limited data; individualized risk-benefit assessment required 1.
  • Pediatrics: Similar principles apply but with heightened vigilance for developmental impacts 1.
  • Elderly: Increased susceptibility to adverse effects; careful monitoring essential 1.
  • Comorbidities: Presence of underlying lung disease may exacerbate drug-induced lung injury; tailored management strategies needed 1.

    • Key Recommendations

  • Identify and Discontinue Offending Drugs Promptly (Evidence: Strong 1).
  • Initiate Corticosteroid Therapy for Severe Cases (Evidence: Moderate 1).
  • Regular Monitoring with HRCT and PFTs is Essential for Follow-Up (Evidence: Moderate 1).

    • References

    1 Bryant DH. Drug-induced pulmonary disease. The Medical journal of Australia 1992. link

    Original source

    1. [1]
      Drug-induced pulmonary disease. — Bryant DH The Medical journal of Australia (1992)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG